Axogen Inc (AXGN) Stock Price, Quote & News

Company Profile

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral...

Industry: Medical Devices

Sector: Healthcare

Phone: 386 462 6800

Fax: 386 462 6801

Website: www.axogeninc.com

Address:

13631 Progress Boulevard, Suite 400, Alachua, United States

LuckEtradER Nov. 11 at 9:53 PM

$AXGN

0 · Reply

dustin1101 Nov. 10 at 7:17 PM

$AXGN About time to see $25??

0 · Reply

Doozio Nov. 8 at 8:23 PM

$AXGN all the way up da Roger because it was always during 🐒🍌🧠⏰♾️

0 · Reply

LuckEtradER Nov. 6 at 10:37 PM

$AXGN

0 · Reply

dustin1101 Nov. 6 at 4:30 PM

$AXGN once again, proving to be an absolute gem in this market.

0 · Reply

LuckEtradER Nov. 3 at 11:09 PM

$AXGN 👀

0 · Reply

dustin1101 Nov. 3 at 5:07 PM

$AXGN This may just break higher here due to lack of sellers.

0 · Reply

aletz Nov. 1 at 6:03 PM

$AXGN https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk1/ AXGN on the list

0 · Reply

dustin1101 Oct. 30 at 3:36 PM

$AXGN Careful of a double top here if mkt pulls back. Short term issue.

0 · Reply

erevnon Oct. 30 at 3:25 PM

Citizens maintains Axogen $AXGN at Market Outperform and raises the price target from $26 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors

BELFB LMB PMTS WLDN

Oct 29, 2025, 2:26 PM EDT - 16 days ago

Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 7:00 AM EDT - 16 days ago

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Oct 1, 2025, 12:30 PM EDT - 6 weeks ago

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

Oct 1, 2025, 10:50 AM EDT - 6 weeks ago

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm

Aug 25, 2025, 6:40 AM EDT - 2 months ago

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Aug 12, 2025, 5:17 AM EDT - 3 months ago

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined

Aug 5, 2025, 1:15 PM EDT - 3 months ago

Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 4:10 PM EDT - 3 months ago

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 22, 2025, 4:05 PM EDT - 4 months ago

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

May 28, 2025, 8:00 AM EDT - 6 months ago

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

May 9, 2025, 3:21 PM EDT - 6 months ago

Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:05 AM EDT - 6 months ago

Axogen, Inc. Reports 2025 First Quarter Financial Results

Apr 24, 2025, 8:04 AM EDT - 7 months ago

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Feb 25, 2025, 1:58 PM EST - 9 months ago

Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 7:10 AM EST - 9 months ago

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Feb 11, 2025, 4:58 PM EST - 9 months ago

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Jan 10, 2025, 5:00 PM EST - 11 months ago

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2025, 8:01 PM EST - 11 months ago

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Nov 9, 2024, 9:53 AM EST - 1 year ago

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Aug 8, 2024, 2:10 PM EDT - 1 year ago

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Axogen, Inc. Announces New Leadership Appointments

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 1, 2024, 7:00 AM EDT - 1 year ago

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

May 28, 2024, 4:30 PM EDT - 1 year ago

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 5, 2024, 1:21 AM EDT - 1 year ago

AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Reports First Quarter 2024 Financial Results

Apr 29, 2024, 4:50 PM EDT - 1 year ago

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Mar 5, 2024, 11:03 AM EST - 1 year ago

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 7:00 AM EST - 1 year ago

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Feb 13, 2024, 4:30 PM EST - 1 year ago

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 2, 2024, 4:15 PM EST - 1 year ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jan 18, 2024, 5:00 PM EST - 1 year ago

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Jan 4, 2024, 4:45 PM EST - 2 years ago

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Jan 4, 2024, 4:40 PM EST - 2 years ago

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Jan 4, 2024, 4:35 PM EST - 2 years ago

Axogen Announces Promotions on Research and Development Team

Dec 26, 2023, 4:15 PM EST - 2 years ago

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Dec 6, 2023, 7:00 AM EST - 2 years ago

Axogen Announces Transition of Finance Team Leadership

Dec 1, 2023, 5:00 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2023, 9:49 AM EST - 2 years ago

AxoGen, Inc. (AXGN) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:00 AM EST - 2 years ago

Axogen, Inc. Reports 2023 Third Quarter Financial Results

Oct 18, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™

Aug 31, 2023, 7:00 AM EDT - 2 years ago

Axogen to Participate at Upcoming Investor Conferences

Aug 21, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio

LuckEtradER Nov. 11 at 9:53 PM

$AXGN

0 · Reply

dustin1101 Nov. 10 at 7:17 PM

$AXGN About time to see $25??

0 · Reply

Doozio Nov. 8 at 8:23 PM

$AXGN all the way up da Roger because it was always during 🐒🍌🧠⏰♾️

0 · Reply

LuckEtradER Nov. 6 at 10:37 PM

$AXGN

0 · Reply

dustin1101 Nov. 6 at 4:30 PM

$AXGN once again, proving to be an absolute gem in this market.

0 · Reply

LuckEtradER Nov. 3 at 11:09 PM

$AXGN 👀

0 · Reply

dustin1101 Nov. 3 at 5:07 PM

$AXGN This may just break higher here due to lack of sellers.

0 · Reply

aletz Nov. 1 at 6:03 PM

$AXGN https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk1/ AXGN on the list

0 · Reply

dustin1101 Oct. 30 at 3:36 PM

$AXGN Careful of a double top here if mkt pulls back. Short term issue.

0 · Reply

erevnon Oct. 30 at 3:25 PM

Citizens maintains Axogen $AXGN at Market Outperform and raises the price target from $26 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

dustin1101 Oct. 30 at 3:28 AM

$AXGN Took about 1/3 off on the way up. Happy with that with an avg ~$10 below current sp… but I’ll be looking to add back anything 20ish and below before Dec 5. Impressive reaction to this ER. Def better than I figured. This is a 💎. Still holding 6200.

0 · Reply

d_risk Oct. 29 at 10:00 PM

$AXGN - Axogen Inc. Common Stock - 10Q - Updated Risk Factors AXGN warns that disruptions at the FDA or other regulators could negatively impact their business. #MedicalDevices #HealthcareSector #FDADisruptions #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/AXGN/10-Q/2025-10-29

0 · Reply

patb99 Oct. 29 at 7:44 PM

$AXGN testing 22$ ☺️ Let see 20$

0 · Reply

WoogieStockBites Oct. 29 at 7:10 PM

$AXGN owner just said something about market dump on news of 25 cut, but this one holds strong. I don't know what market dump or "25 cut" mean but woogie say woof woof woof for this one

0 · Reply

WoogieStockBites Oct. 29 at 6:48 PM

$AXGN owner going to be home, I was a bad boy today and posted to many things that I hear. I am going to get in trouble, but this seemed to be the most important word I heads today "axgn"... woof woof woof

0 · Reply

patb99 Oct. 29 at 6:37 PM

$AXGN here we go Let see 20$ 🧐

0 · Reply

topstockalerts Oct. 29 at 6:12 PM

$AXGN showing high relative strength.. Stay tuned for more!

0 · Reply

WoogieStockBites Oct. 29 at 6:02 PM

0 · Reply

WoogieStockBites Oct. 29 at 6:01 PM

$AXGN woof! Couldn't understand much but a human from a bank company did say they wouldn't short this in their portfolio? i dont know what that means because I only hear english sometimes and don't know what it means

0 · Reply

50shadesoftrades Oct. 29 at 5:59 PM

$NPT AHMA $WVE $MCTA PBSB $YYGH $EDHL $AXGN Intraday gainers

0 · Reply

patb99 Oct. 29 at 5:30 PM

$AXGN we should see 20$ back by eod

0 · Reply

topstockalerts Oct. 29 at 4:39 PM

Top Gainers PT2 $MAMK $GNTA $AXGN $NPT $MENS

0 · Reply

Market Cap	1.11B
Revenue (ttm)	187.34M
Net Income (ttm)	-9.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5.32%
Debt to Equity Ratio	0.40

Volume	490,500
Avg Vol	867,058
Day's Range	N/A - N/A
Shares Out	46.12M
Stochastic %K	32%
Beta	1.09
Analysts	Strong Sell
Price Target	$28.50